Clinical trial · Interventional
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
NCT02754141CI-TRIAL-00065346completedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Solid Tumor | Malignant Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986179 | Biological | — | UNRESOLVED |
| Nivolumab | Biological | Nivolumab | ALIAS |
| rHuPH20 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Arm A-Monotherapy
- description
- BMS-986179, dose as specified
- interventionNames
- Biological: BMS-986179
- type
- EXPERIMENTAL
- label
- Arm B- Combination Therapy
- description
- BMS-986179 + nivolumab, dose as specified
- interventionNames
- Biological: BMS-986179
- Biological: Nivolumab
- type
- EXPERIMENTAL
- label
- Arm C-Combination Therapy
- description
- BMS-986179 + rHuPH20, dose as specified
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Solid cancers that are advanced or have spread (for which alternative therapies were deemed not effective) * Eastern Cooperative Oncology Group (ECOG) 0-1 * Acceptable lab testing results * Allow biopsies Exclusion Criteria: * Central nervous system (CNS) tumors * Uncontrolled or significant cardiovascular diseases * Active or known autoimmune disease * Organ transplant Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.